A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan. (HIZ)

Pfizer

Status: Active, not recruiting

Conditions: Hemophilia A or B

Treatments: Drug: Marstacimab

Study type: Observational

Funder types: Industry

Identifiers

NCT07161687

B7841012

Details and patient eligibility

About

A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.

Full description

The objective of this study is to assess the safety of this drug under actual usage conditions in patients with congenital hemophilia who do not have inhibitors.

The observation period will be up to three years. However, for cases in which administration of the drug is discontinued, information will be collected up to the point of discontinuation.

Enrollment: 50 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

• Patients who have received at least one dose of this drug after the launch of this drug

Trial design

50 participants in 1 patient group

Marstacimab

Description:

hemophilia patients without inhibitor

Treatment:

Drug: Marstacimab